Artículos por temáticas
En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.
Tema
Enfermedad de Parkinson
2030 ARTíCULOS , VIENDO DEL 1 AL 15
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.
Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ.
Brain. 2010 Nov;133(11):3434-43. doi: 10.1093/brain/awq268.
0
0
0
Fatigue in Parkinson's disease: prevalence and associated factors.
Beiske AG, Loge JH, Hjermstad MJ, Svensson E.
Mov Disord. 2010 Oct 30;25(14):2456-60. doi: 10.1002/mds.23372.
0
0
0
Pinnock RA, McGivern RC, Forbes R, Gibson JM.
J Neurol. 2010 Apr;257(4):533-9. doi: 10.1007/s00415-009-5356-3.
0
0
0
Shu X, Wang G, Lu X, Xie Y.
Rheumatol Int. 2010 Sep;30(11):1493-7. doi: 10.1007/s00296-009-1094-1. Review.
0
0
0
Mace JL, Porter RJ, Dalrymple-Alford JC, Wesnes KA, Anderson TJ.
J Psychopharmacol. 2010 Oct;24(10):1465-72. doi: 10.1177/0269881109105721.
0
0
0
Allert N, Lehrke R, Sturm V, Volkmann J.
J Neural Transm (Vienna). 2010 Mar;117(3):349-51. doi: 10.1007/s00702-009-0363-1.
0
0
0
Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.
Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, Weintraub D.
Mov Disord. 2010 Aug 15;25(11):1660-9. doi: 10.1002/mds.23147.
0
0
0
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ.
Neurology. 2010 Jan 5;74(1):77-84. doi: 10.1212/WNL.0b013e3181c7da8e.
0
0
0
Problems associated with fluid biomarkers for Parkinson's disease.
Nyhlén J, Constantinescu R, Zetterberg H.
Biomark Med. 2010 Oct;4(5):671-81. doi: 10.2217/bmm.10.84. Review.
0
0
0
Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease.
Leite MA, Nascimento OJ.
Eur J Neurol. 2010 Feb;17(2):e9; author reply e10. doi: 10.1111/j.1468-1331.2009.02863.x. No abstract available.
0
0
0
Depression, Parkinson disease, Alzheimer disease. The homocysteine hypothesis.
Sui R, Zhang L.
Neurosciences (Riyadh). 2010 Jul;15(3):211-3. No abstract available.
0
0
0
Margis R, Donis KC, Schönwald SV, Rieder CR.
Rev Bras Psiquiatr. 2010 Jun;32(2):125-31.
0
0
0
Rehabilitation in Parkinson's disease: assessing the outcome using objective metabolic measurements.
Frazzitta G, Maestri R, Bertotti G, Uccellini D, Bazzini G, Abelli P, Aquilani R.
Mov Disord. 2010 Apr 15;25(5):609-14. doi: 10.1002/mds.22871.
0
0
0
Transdermal rotigotine for the perioperative management of Parkinson's disease.
Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, Häck HJ, Boroojerdi B, Reichmann H; NEUPOS Study Group..
J Neural Transm (Vienna). 2010 Jul;117(7):855-9. doi: 10.1007/s00702-010-0425-4.
0
0
0
Risk of Parkinson's disease after tamoxifen treatment.
Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL.
BMC Neurol. 2010 Apr 12;10:23. doi: 10.1186/1471-2377-10-23.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
